SITE002-0237

completed

Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE002 (USA) (Dr. Nolan) · consented 2022-11-27

Adverse events

Serious AEs

Open data queries

Luna dropout signal

–

Adverse events

severe assessed 2026-08-18

Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-01-01 (study day 15); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-01-18 (study day 32); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-04-21 (study day 125); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-06-19 (study day 184); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-01-17 (study day 396); relationship: N

severe serious assessed 2026-08-18

Grade 4 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-01-20 (study day 399); relationship: not assessed; serious criteria: life-threatening

moderate assessed 2026-08-18

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-02-11 (study day 421); relationship: not assessed

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.